LENZ Therapeutics (LENZ) Q3 2026 earnings summary

Executive summary

• Q3 VIZZ product sales rose 50% QoQ to $2.6 million; demand momentum continued into Q4, supported by telehealth access and consumer marketing.

• A Q4 reorganization will prioritize consumer marketing and sales-growth initiatives, with projected 2027 operating expenses reduced by more than 50%.

Financial highlights

• Q3 2026 total revenue was $3.4 million, including $2.6 million in product sales and $0.8 million in license revenue; Q3 2025 revenue was $12.5 million, all license revenue.

• Nine-month 2026 revenue was $10.8 million, including $6.0 million in product sales and $4.8 million in license revenue, versus $17.5 million in nine-month 2025 license revenue.

• Net loss was $31.0 million, or $0.99 per share, in Q3 2026 and $104.4 million, or $3.33 per share, for nine-month 2026; prior-year losses were $16.7 million and $46.2 million, respectively.

Outlook and guidance

• Projected 2027 operating expenses target $70 million to $75 million, excluding stock-based compensation, representing a reduction of more than 50%.

• Reorganization activities are expected to be substantially completed in Q4 2026, with estimated one-time net restructuring charges of $5 million.

• Consumer awareness, access and adoption of VIZZ are the stated commercial priorities; management cited demand momentum continuing into Q4.